Emerging investigations on retatrutides, a dual agonist for incretin hormone and glucose-dependent insulinotropic polypeptide, indicate encouraging results in managing weight gain and type 2 diabetic condition. Preliminary data from clinical trials point to notable decreases in body mass and enhanced glucose levels. Further exploration is focused o